MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 1, 2014, Pages 32-40

  Li, Xiao Yu ^a   Luo, Qi Feng ^a   Wei, Chuan Kui ^a   Li, Deng Feng ^a   Li, Jia ^a   Fang, Lin ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Breast cancer; CDK8; MiR 107

Indexed keywords

EID: 84892621486     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nieto Y, Nawaz F, Jones RB, Shpall EJ and Nawaz S. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 2009; 27: 5919-5923.
2. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L'Abbe D, Yu Z and Shen SH. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 2008; 29: 1710-1716.
3. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
4. Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, Lin MT, Chu CY, Hua KT, Chen CN, Kuo TC, Chang, KJ, Hsiao M, Chang YW, Chen JS, Yang PC and Kuo ML. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest 2011; 121: 3442-3455.
5. Feng L, Xie Y, Zhang H and Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol 2012; 29: 856-863.
6. Moncini S, Salvi A, Zuccotti P, Viero G, Quattrone A, Barlati S, De Petro G, Venturin M and Riva P. The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS One 2011; 6: e20038.
7. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM and Firestein R. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res 2012; 72: 2129-2139.
8. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM and Firestein R. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008; 455: 552-556.
9. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M and Hahn WC. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008; 455: 547-551.
10. Bryan BB, Schnitt SJ and Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19: 617-621.
11. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K and Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and-2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU international 2006; 98: 661-667.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M and Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
13. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX and Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-2360.
14. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D and Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumor spheres. BMC Cancer 2008; 8: 266.
15. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA and Agami R. Regulation of the adenomatous polyposiscoli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802.
16. Liu W, Gong YH, Chao TF, Peng XZ, Yuan JG, Ma ZY, Jia G and Zhao JZ. Identification of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J (Engl) 2009; 122: 2405-2411.
17. Sharma PS, Sharma R and Tyagi R. Inhibitiors of cyclin depentent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 2008; 8: 53-75.
18. Senderowicz AM and Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376-387.
19. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J and Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22: 2234-2240.
20. Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E, Martin-Castillo B, Del Barco S, Brunet J and Menendez JA. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol 2008; 33: 1165-1176.